The Therac-25, a linear accelerator designed for cancer treatment, promised a new era in medical technology. Developed by Atomic Energy of Canada Limited (AECL) in 1976, it aimed to deliver precise radiation doses to tumors, minimizing damage to surrounding healthy tissue.
Unlike its predecessors, the Therac-25 was controlled by software, a novel approach that allowed for more complex and flexible operation. This shift from mechanical to digital was seen as a significant advancement, offering greater efficiency and adaptability in treatments. However, this reliance on software also introduced new risks, as the tragic events that unfolded would reveal.